Clinical & Translational Immunology

Article	Citations
Endothelial cells are not productively infected by SARS‐CoV‐2	86
Antibodies against type I interferon: detection and association with severe clinical outcome in COVID‐19 patients	73
CAR‐NK cells: the next wave of cellular therapy for cancer	65
A scalable serology solution for profiling humoral immune responses to SARS‐CoV‐2 infection and vaccination	60
Comprehensive analysis of SARS‐CoV‐2 antibody dynamics in New Zealand	47
Preclinical development of a molecular clamp‐stabilised subunit vaccine for severe acute respiratory syndrome coronavirus 2	45
Dynamics of antibodies to SARS‐CoV‐2 in convalescent plasma donors	44
Allogeneic CD20‐targeted γδ T cells exhibit innate and adaptive antitumor activities in preclinical B‐cell lymphoma models	42
Pattern of circulating SARS‐CoV‐2‐specific antibody‐secreting and memory B‐cell generation in patients with acute COVID‐19	41
Patient‐derived organoids of bladder cancer recapitulate antigen expression profiles and serve as a personal evaluation model for CAR‐T cells in vitro	39
Rheumatoid arthritis CD14+ monocytes display metabolic and inflammatory dysfunction, a phenotype that precedes clinical manifestation of disease	38
Arrested development: suppression of NK cell function in the tumor microenvironment	36
SARS‐CoV‐2‐specific humoral and cellular immunity persists through 9 months irrespective of COVID‐19 severity at hospitalisation	34
Kinetics of peripheral blood neutrophils in severe coronavirus disease 2019	34
Decline in neutralising antibody responses, but sustained T‐cell immunity, in COVID‐19 patients at 7 months post‐infection	34
Type 1 conventional dendritic cells and interferons are required for spontaneous CD4+ and CD8+ T‐cell protective responses to breast cancer	34
RGD‐binding integrins and TGF‐β in SARS‐CoV‐2 infections – novel targets to treat COVID‐19 patients?	32
Pathogenesis of autoimmune demyelination: from multiple sclerosis to neuromyelitis optica spectrum disorders and myelin oligodendrocyte glycoprotein antibody‐associated disease	31
The complex interplay between endoplasmic reticulum stress and the NLRP3 inflammasome: a potential therapeutic target for inflammatory disorders	30
The up‐to‐date pathophysiology of Kawasaki disease	30
Natural killer cells in inflammatory autoimmune diseases	29
Cerebrospinal fluid metabolomics: detection of neuroinflammation in human central nervous system disease	29
Cardiovascular disease in SARS‐CoV‐2 infection	28
Robust correlations across six SARS‐CoV‐2 serology assays detecting distinct antibody features	26
Prophylactic antigen‐specific T‐cells targeting seven viral and fungal pathogens after allogeneic haemopoietic stem cell transplant	26

Lysine methyltransferase G9a is an important modulator of trained immunity	25
Ligelizumab treatment for severe asthma: learnings from the clinical development programme	25
Influenza, but not SARS‐CoV‐2, infection induces a rapid interferon response that wanes with age and diminished tissue‐resident memory CD8+ T cells	25
Systematic evaluation of SARS‐CoV‐2 antigens enables a highly specific and sensitive multiplex serological COVID‐19 assay	24
Molecular and cellular mechanisms of itch and pain in atopic dermatitis and implications for novel therapeutics	23
TGF‐β‐secreting regulatory B cells: unsung players in immune regulation	23
An acetate‐yielding diet imprints an immune and anti‐microbial programme against enteric infection	23
High levels of soluble CD25 in COVID‐19 severity suggest a divergence between anti‐viral and pro‐inflammatory T‐cell responses	23
Circular RNA TRAPPC6B inhibits intracellular Mycobacterium tuberculosis growth while inducing autophagy in macrophages by targeting microRNA‐874‐3p	21
Humoral immunity against SARS‐CoV‐2 variants including omicron in solid organ transplant recipients after three doses of a COVID‐19 mRNA vaccine	21
Off‐target effects of bacillus Calmette–Guérin vaccination on immune responses to SARS‐CoV‐2: implications for protection against severe COVID‐19	21
Blunted sFasL signalling exacerbates TNF‐driven neutrophil necroptosis in critically ill COVID‐19 patients	19
Heterogeneous magnitude of immunological memory to SARS‐CoV‐2 in recovered individuals	19
Modelling the tumor immune microenvironment for precision immunotherapy	18
Improvement of Treg immune response after treatment with tocilizumab in giant cell arteritis	18
Impact of SARS‐CoV‐2 infection on vaccine‐induced immune responses over time	17
Inflammatory marker trajectories associated with frailty and ageing in a 20‐year longitudinal study	17
Memory stem T cells modified with a redesigned CD30‐chimeric antigen receptor show an enhanced antitumor effect in Hodgkin lymphoma	17
Optimising the IgG‐degrading enzyme treatment regimen for enhanced adeno‐associated virus transduction in the presence of neutralising antibodies	17
Circulating CD8+ mucosal‐associated invariant T cells correlate with improved treatment responses and overall survival in anti‐PD‐1‐treated melanoma patients	17
Nalfurafine reduces neuroinflammation and drives remyelination in models of CNS demyelinating disease	16
Characteristics of T‐cell responses in COVID‐19 patients with prolonged SARS‐CoV‐2 positivity – a cohort study	16
Increased GM‐CSF‐producing NCR‐ ILC3s and neutrophils in the intestinal mucosa exacerbate inflammatory bowel disease	16
Human neutralising antibodies elicited by SARS‐CoV‐2 non‐D614G variants offer cross‐protection against the SARS‐CoV‐2 D614G variant	16
Landscape of T‐cell repertoires with public COVID‐19‐associated T‐cell receptors in pre‐pandemic risk cohorts	16
Autoantibodies against complement component C1q in systemic lupus erythematosus	16
SLAMF8 expression predicts the efficacy of anti‐PD1 immunotherapy in gastrointestinal cancers	16
T‐cell response after first dose of BNT162b2 SARS‐CoV‐2 vaccine among healthcare workers with previous infection or cross‐reactive immunity	15
Differential transcriptional and functional properties of regulatory T cells in HIV‐infected individuals on antiretroviral therapy and long‐term non‐progressors	15
Tear antibodies to SARS‐CoV‐2: implications for transmission	15
Whole‐blood cytokine secretion assay as a high‐throughput alternative for assessing the cell‐mediated immunity profile after two doses of an adjuvanted SARS‐CoV‐2 recombinant protein vaccine candidate	15
Proinsulin‐specific T‐cell responses correlate with estimated c‐peptide and predict partial remission duration in type 1 diabetes	15
Novel high‐affinity EGFRvIII‐specific chimeric antigen receptor T cells effectively eliminate human glioblastoma	15
C‐reactive protein flare‐response predicts long‐term efficacy to first‐line anti‐PD‐1‐based combination therapy in metastatic renal cell carcinoma	15
Sustained low‐dose interleukin‐2 therapy alleviates pathogenic humoral immunity via elevating the Tfr/Tfh ratio in lupus	14
Inflammation neuroscience: neuro‐immune crosstalk and interfaces	14
Quantification and role of innate lymphoid cell subsets in Chronic Obstructive Pulmonary Disease	14
Tumor‐associated neutrophils (TANs) in human carcinoma‐draining lymph nodes: a novel TAN compartment	14
SARS‐CoV‐2 triggers complement activation through interactions with heparan sulfate	14
Mutated GM‐CSF‐based CAR‐T cells targeting CD116/CD131 complexes exhibit enhanced anti‐tumor effects against acute myeloid leukaemia	14
IL‐17 drives salivary gland dysfunction via inhibiting TRPC1‐mediated calcium movement in Sjögren’s syndrome	14
Adaptive immunity to human coronaviruses is widespread but low in magnitude	13
Epigenetic programming underpins B‐cell dysfunction in peanut and multi‐food allergy	13
Next‐generation Bruton's tyrosine kinase inhibitor BIIB091 selectively and potently inhibits B cell and Fc receptor signaling and downstream functions in B cells and myeloid cells	13
Perivascular macrophages create an intravascular niche for CD8+ T cell localisation prior to the onset of fatal experimental cerebral malaria	13
Regulation of the human NK cell compartment by pathogens and vaccines	13
Adenoviral vector‐based platforms for developing effective vaccines to combat respiratory viral infections	13
Antibodies to neutralising epitopes synergistically block the interaction of the receptor‐binding domain of SARS‐CoV‐2 to ACE 2	13
IgM and IgA augmented autoantibody signatures improve early‐stage detection of colorectal cancer prior to nodal and distant spread	13
Glycolipid‐peptide conjugate vaccines elicit CD8+ T‐cell responses and prevent breast cancer metastasis	12

Inflammasome activation: from molecular mechanisms to autoinflammation	12
Exploiting the CRISPR‐Cas9 gene‐editing system for human cancers and immunotherapy	12
Parallel detection of SARS‐CoV‐2 epitopes reveals dynamic immunodominance profiles of CD8+ T memory cells in convalescent COVID‐19 donors	11
Impact of adaptive natural killer cells, KLRC2 genotype and cytomegalovirus reactivation on late mortality in patients with severe COVID‐19 lung disease	11
Novel high‐affinity EGFRvIII‐specific chimeric antigen receptor T cells effectively eliminate human glioblastoma	11
Rapid whole‐blood assay to detect SARS‐CoV‐2‐specific memory T‐cell immunity following a single dose of AstraZeneca ChAdOx1‐S COVID‐19 vaccine	11
YTHDF2 promotes temozolomide resistance in glioblastoma by activation of the Akt and NF‐κB signalling pathways via inhibiting EPHB3 and TNFAIP3	10
Adoptive T‐cell therapy targeting Epstein–Barr virus as a treatment for multiple sclerosis	10
Intratumoral injection of caerin 1.1 and 1.9 peptides increases the efficacy of vaccinated TC‐1 tumor‐bearing mice with PD‐1 blockade by modulating macrophage heterogeneity and the activation of CD8	10
No evidence that plasmablasts transdifferentiate into developing neutrophils in severe COVID‐19 disease	10
High‐resolution analysis of individual spike peptide‐specific CD4+ T‐cell responses in vaccine recipients and COVID‐19 patients	10
TIGIT blockade enhances NK cell activity against autologous HIV‐1‐infected CD4+ T cells	10
High expression of CD38 and MHC class II on CD8+ T cells during severe influenza disease reflects bystander activation and trogocytosis	10
SARS‐CoV‐2 sculpts the immune system to induce sustained virus‐specific naïve‐like and memory B‐cell responses	10
Designing the next‐generation therapeutic vaccines to cure chronic hepatitis B: focus on antigen presentation, vaccine properties and effect measures	10
Effect of washed versus unwashed red blood cells on transfusion‐related immune responses in preterm newborns	9
Human regulatory T cells locally differentiate and are functionally heterogeneous within the inflamed arthritic joint	9
Understanding the tumor microenvironment in head and neck squamous cell carcinoma	9
Epstein–Barr virus and multiple sclerosis: moving from questions of association to questions of mechanism	9
Validation and performance of a multiplex serology assay to quantify antibody responses following SARS‐CoV‐2 infection or vaccination	9
Severe COVID‐19 represents an undiagnosed primary immunodeficiency in a high proportion of infected individuals	8
Detailed bladder cancer immunoprofiling reveals new clues for immunotherapeutic strategies	8
Activity of the growth hormone‐releasing hormone antagonist MIA602 and its underlying mechanisms of action in sarcoidosis‐like granuloma	8
LIR‐1 educates expanded human NK cells and defines a unique antitumor NK cell subset with potent antibody‐dependent cellular cytotoxicity	8
Deficient DNASE1L3 facilitates neutrophil extracellular traps‐induced invasion via cyclic GMP‐AMP synthase and the non‐canonical NF‐κB pathway in diabetic hepatocellular carcinoma	8
Interleukin‐1 pathway in active large vessel vasculitis patients with a poor prognosis: a longitudinal transcriptome analysis	8
A lymphodepleted non‐human primate model for the assessment of acute on‐target and off‐tumor toxicity of human chimeric antigen receptor‐T cells	8
Quantitative measurement of IgG to SARS‐CoV‐2 antigens using monoclonal antibody‐based enzyme‐linked immunosorbent assays	8
Serological and cellular inflammatory signatures in end‐stage kidney disease and latent tuberculosis	8
Epigenetic regulation of inflammation by microRNAs in post‐infectious bronchiolitis obliterans	8
IL‐6 receptor blockade for allograft dysfunction after lung transplantation in a patient with COPA syndrome	8
Previous SARS‐CoV‐2 infection or a third dose of vaccine elicited cross‐variant neutralising antibodies in vaccinated solid‐organ transplant recipients	8
Retrospective analysis of the efficacy of adjuvant cytokine‐induced killer cell immunotherapy combined with chemotherapy in colorectal cancer patients after surgery	8
An autologous colonic organoid‐derived monolayer model to study immune: bacterial interactions in Crohn's disease patients	8
Hypothesis: Febrile infection‐related epilepsy syndrome is a microglial NLRP3 inflammasome/IL‐1 axis‐driven autoinflammatory syndrome	8
Generation of plasma cells and CD27−IgD− B cells during hantavirus infection is associated with distinct pathological findings	7
The immunological link between neonatal lung and eye disease	7
Dysfunctional BTN3A together with deregulated immune checkpoints and type I/II IFN dictate defective interplay between pDCs and γδ T cells in melanoma patients, which impacts clinical outcomes	7
Bactericidal fully human single‐chain fragment variable antibodies protect mice against methicillin‐resistant Staphylococcusaureus bacteraemia	7
Supranutritional selenium suppresses ROS‐induced generation of RANKL‐expressing osteoclastogenic CD4+ T cells and ameliorates rheumatoid arthritis	7
G‐CSF induces CD15+ CD14+ cells from granulocytes early in the physiological environment of pregnancy and the cancer immunosuppressive microenvironment	7
TGF‐β‐activated kinase‐1 inhibitor LL‐Z1640‐2 reduces joint inflammation and bone destruction in mouse models of rheumatoid arthritis by inhibiting NLRP3 inflammasome, TACE, TNF‐α and RANKL expression	7
Increased mast cell activation in eosinophilic chronic obstructive pulmonary disease	7
The contribution of the alternative pathway in complement activation on cell surfaces depends on the strength of classical pathway initiation	7
A novel dual NLRP1 and NLRP3 inflammasome inhibitor for the treatment of inflammatory diseases	6
Immunoregulatory effects of testosterone supplementation combined with exercise training in men with Inclusion Body Myositis: a double‐blind, placebo‐controlled, cross‐over trial	6
Primary immunodeficiency‐related genes in neonatal intensive care unit patients with various genetic immune abnormalities: a multicentre study in China	6
The average copy number variation (CNVA) of chromosome fragments is a potential surrogate for tumor mutational burden in predicting responses to immunotherapy in non‐small‐cell lung cancer	6
Targeting SARS‐CoV‐2 infection through CAR‐T‐like bispecific T cell engagers incorporating ACE2	6
The myeloid cell type I IFN system promotes antitumor immunity over pro‐tumoral inflammation in cancer T‐cell therapy	6
Diabetes induced by checkpoint inhibition in nonobese diabetic mice can be prevented or reversed by a JAK1/JAK2 inhibitor	6
The IL‐27/IL‐27R axis is altered in CD4+ and CD8+ T lymphocytes from multiple sclerosis patients	6
SKI‐G‐801, an AXL kinase inhibitor, blocks metastasis through inducing anti‐tumor immune responses and potentiates anti‐PD‐1 therapy in mouse cancer models	6
Epstein–Barr virus infection, B‐cell dysfunction and other risk factors converge in gut‐associated lymphoid tissue to drive the immunopathogenesis of multiple sclerosis: a hypothesis	6
Diversification of circulating and tumor‐infiltrating plasmacytoid DCs towards the P3 (CD80+ PDL1−)‐pDC subset negatively correlated with clinical outcomes in melanoma patients	6
Localised release of matrix metallopeptidase 8 in fatal cerebral malaria	6
Expression of CD49f defines subsets of human regulatory T cells with divergent transcriptional landscape and function that correlate with ulcerative colitis disease activity	5
Native and oxidised lipoproteins negatively regulate the serum amyloid A‐induced NLRP3 inflammasome activation in human macrophages	5
The efficacy and safety of the combination of axitinib and pembrolizumab‐activated autologous DC‐CIK cell immunotherapy for patients with advanced renal cell carcinoma: a phase 2 study	5
Combinatorial liposomal peptide vaccine induces IgA and confers protection against influenza virus and bacterial super‐infection	5
From bedside to bench: how existing therapies inform the relationship between Epstein–Barr virus and multiple sclerosis	5
IFN‐γ facilitates liver fibrogenesis by CD161+CD4+ T cells through a regenerative IL‐23/IL‐17 axis in chronic hepatitis B virus infection	5
Blood transcriptomics identifies immune signatures indicative of infectious complications in childhood cancer patients with febrile neutropenia	5
Epigenetic modulation enhances immunotherapy for pancreatic ductal adenocarcinoma	5
Genome‐wide off‐target analyses of CRISPR/Cas9‐mediated T‐cell receptor engineering in primary human T cells	5
Increased amphiregulin expression by CD4+ T cells from individuals with asymptomatic Leishmania donovani infection	5
The interaction between Epstein–Barr virus and multiple sclerosis genetic risk loci: insights into disease pathogenesis and therapeutic opportunities	5
Peripheral autoreactive CD8 T‐cell frequencies are too variable to be a reliable predictor of disease progression of human type 1 diabetes	5
Importance of crosstalk between the microbiota and the neuroimmune system for tissue homeostasis	5
DOCK8 deficiency diminishes thymic T‐regulatory cell development but not thymic deletion	5
Neutrophils contribute to elevated BAFF levels to modulate adaptive immunity in patients with primary immune thrombocytopenia by CD62P and PSGL1 interaction	5
Vaccine‐related major cutaneous reaction size correlates with cellular‐mediated immune responses after tularaemia immunisation	5
Impact of maternal engrafted cytomegalovirus‐specific CD8+ T cells in a patient with severe combined immunodeficiency	4
Metagenomic profiling reveals dominance of gram‐positive bacteria in the gut microbiome shifts associated with immunoglobulin A vasculitis (Henoch–Schönlein Purpura)	4
Genetic risk for severe COVID‐19 correlates with lower inflammatory marker levels in a SARS‐CoV‐2‐negative cohort	4
High sensitivity and specificity of a 5‐analyte protein and microRNA biosignature for identification of active tuberculosis	4
Cord blood group 2 innate lymphoid cells are associated with lung function at 6 weeks of age	4
Naturally derived cytokine peptides limit virus replication and severe disease during influenza A virus infection	4
The immunopathogenesis of SARS‐CoV‐2 infection in children: diagnostics, treatment and prevention	4
Heterologous SARS‐CoV‐2 IgA neutralising antibody responses in convalescent plasma	4

IL‐33/ST2 axis deficiency exacerbates neutrophil‐dominant allergic airway inflammation	4
Preclinical evaluation of cancer immune therapy using patient‐derived tumor antigen‐specific T cells in a novel xenograft platform	4
Extreme prematurity and sepsis strongly influence frequencies and functional characteristics of circulating γδ T and natural killer cells	4
Categorisation of patients based on immune profiles: a new approach to identifying candidates for response to checkpoint inhibitors	4
Roadmap for understanding mechanisms on how Epstein–Barr virus triggers multiple sclerosis and for translating these discoveries in clinical trials	4
Dupilumab provides early and durable improvement of symptoms in patients with chronic rhinosinusitis with nasal polyps	4
Pervasive inflammatory activation in patients with deficiency in very‐long‐chain acyl‐coA dehydrogenase (VLCADD)	4
Repeated influenza vaccination provides cumulative protection from distinct H3N2 viruses	4
Homologous peptides derived from influenza A, B and C viruses induce variable CD8+ T cell responses with cross‐reactive potential	4
Effect of Intralipid infusion on peripheral blood T cells and plasma cytokines in women undergoing assisted reproduction treatment	4
Probabilistic classification of anti‐SARS‐CoV‐2 antibody responses improves seroprevalence estimates	4